Introduction
Thyroid nodules are a frequent clinical finding for which the exclusion of thyroid cancer or thyroid autonomy is necessary. The management of thyroid nodules has significantly changed due to the widespread availability of novel diagnostic and therapeutic resources. Imaging techniques and laboratory tests are continuously improving the assessment of the risk of malignancy and of the function status of thyroid nodular disease.
This document is unique because it represents collaboration and consensus between associations on both sides of the Atlantic. It was prepared as a collaborative effort of the American Association of Clinical Endocrinologists (AACE), the Italian Association of Clinical Endocrinologists (AME), and the European Thyroid Association (ETA).
These guidelines cover diagnostic and therapeutic aspects of thyroid nodular diseases. They do not cover thyroid cancer management. The evidence level of each reference was rated on a scale of 1 to 4 and the strength of the recommendations was graded on the basis of grade designations A (action based on strong evidence) through D (action not based on any evidence or not recommended). The best evidence level (BEL), corresponding to the best conclusive evidence found, accompanies the recommendation grade. All recommendations resulted from a consensus among the AACE, AME, and ETA primary writers and were influenced by input from the Task Force members and reviewers.
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The Scope of the Problem
Thyroid nodules are common, with an estimated prevalence ranging from 3% to 7% on the basis of palpation. The prevalence of incidental thyroid nodules detected by US is estimated to be 20% to 76% in the general population. Moreover, 20% to 48% of patients with one palpable thyroid nodule are found to have additional nodules when investigated by US. 
Clinical Evaluation and Diagnosis
FNA Biopsy of Multinodular Glands
• It is rarely necessary to biopsy more than 2 nodules when they are selected on the basis of previously described criteria 
FNA Biopsy of Thyroid Incidentalomas
• Thyroid incidentalomas should be managed according to previously described criteria for nodule diagnosis • Incidentalomas detected by CT or MRI should undergo US evaluation before consideration for UGFNA biopsy • Incidentalomas detected by positron emission tomography with 18 F-fluorodeoxyglucose should undergo US evaluation plus UGFNA biopsy because of the high risk of malignancy C; 3 C; 3 C; 3
Other Diagnostic Imaging Techniques
Grade; BEL
• MRI and CT are not indicated for routine thyroid nodule evaluation • MRI and CT are of value for assessment of size, airway compression, or substernal extension of a nodular goiter D C; 3
Novel US Techniques
• Elastography and US contrast media currently are not used routinely in the evaluation of thyroid nodules C; 3 • Presence of local pressure symptoms clearly associated with the nodule(s), previous external irradiation, progressive nodule growth, suspicious US features, or cosmetic issues • The preferred extent of resection for benign uninodular goiter is lobectomy plus isthmectomy and for MNG is (near) total thyroidectomy D D
US-Guided Percutaneous Ethanol Injection
• Percutaneous ethanol injection is effective in the treatment of benign thyroid cysts and complex nodules with a large fluid component • Percutaneous ethanol injection should not be performed in solitary solid nodules, whether hyperfunctioning or not, or in MNGs B; 1 C; 3
Image-Guided Thermal Ablation
• Laser ablation may be considered for the treatment of thyroid nodules causing pressure symptoms or cosmetic issues in patients who decline surgery or are at surgical risk. Its use should be restricted to specialized centers • RFA is not recommended in the routine management of thyroid nodules C; 2 C; 3
Radioiodine Therapy for Benign Nodular Goiter
Considerations
• Indications are hyperfunctioning and/or symptomatic goiter, previous thyroid surgery, or surgical risk • Before treatment, UGFNA biopsy should be performed per the recommendations given for nontoxic MNG • Avoid use of iodine contrast agents or iodinated drugs before administration of radioiodine; withdraw antithyroid drugs at least 1 week before treatment and consider resumption 1 week after radioiodine therapy 
Pregnancy and Childhood
Management of Thyroid Nodules During Pregnancy
• Thyroid nodules in pregnant women should be managed in the same way as in nonpregnant women; in the presence of suspicious clinical or US findings, diagnosis necessitates FNA biopsy • Avoid use of radioactive agents for both diagnostic and therapeutic purposes • During pregnancy, suppressive levothyroxine therapy for thyroid nodules is not recommended • For a growing thyroid nodule during pregnancy, follow-up should include US and FNA biopsy • If FNA biopsy shows a follicular lesion, surgery may be deferred until after delivery C; 3 A; 2 C; 3 C; 3 C; 3
Management of FNA Biopsy-Malignant Nodules During Pregnancy
• When a diagnosis of thyroid malignancy is made during the first or second trimester, thyroidectomy may be done during the second trimester, if recommended. Women with no evidence of aggressive thyroid cancer may be reassured that surgical treatment performed soon after delivery is unlikely to adversely affect prognosis • When a diagnosis of thyroid malignancy is made during the third trimester, surgical treatment can be deferred until the immediate postpartum period C; 3 C; 3
Management of Thyroid Nodules in Children
• Evaluation of nodular disease in children is similar to that in adults • Because of a higher prevalence of malignancy in children, surgery is often necessary for cold as well as hot nodules C; 3 C; 3
